“Indirect Tax I Indirect Tax Litigation I Customs & FTP I Central Licensing I Arbitration I Advisory”
Dated: 22.08.2025
CDSCO Issues 2nd Amendment to Drugs Rules-1945
The Ministry of Health and Family Welfare has introduced significant amendments to the Drugs Rules, 1945, through a notification dated August 18, 2025. These changes aim to enhance transparency and ensure better compliance with the Drugs and Cosmetics Act, 1940. The amendments, officially titled the Drugs (2nd Amendment) Rules, 2025, will come into effect on March 1, 2026. Here’s a detailed overview of the key updates and their implications for the pharmaceutical industry.
Background
The draft rules for these amendments were initially published on July 12, 2024, inviting objections and suggestions from stakeholders. After thorough consideration of public feedback and consultation with the Drugs Technical Advisory Board, the Central Government finalized the amendments to improve drug labeling and consumer information.
Key Amendments
- Rule 96 Updates
- Clause (vii): The wording for “date of expiry; and” has been revised to “date of expiry.” This change simplifies the language for better clarity.
- Clause (ix): A new clause has been added, mandating the inclusion of “qualitative details of excipients” on drug labels. Excipients are inactive substances used in drug formulations, and this update ensures that consumers and healthcare professionals have access to detailed information about these components.
Implications for the Pharmaceutical Industry
The inclusion of qualitative details of excipients is a significant step forward in promoting transparency. It allows consumers and healthcare providers to make informed decisions, especially for individuals with allergies or sensitivities to certain excipients. Pharmaceutical companies will need to update their labeling practices to comply with these new requirements by March 1, 2026.
Conclusion
The Drugs (2nd Amendment) Rules, 2025, reflect the government’s commitment to improving drug safety and consumer awareness. As the implementation date approaches, stakeholders in the pharmaceutical industry must prepare to align their practices with these new regulations. These changes not only enhance compliance but also foster trust and transparency in the healthcare sector.
Listen to this on our #YouTube Channel
In case you face any issues related to Indirect Tax-Customs, GST, Foreign Trade Policy (FTP), Arbitration matters and Central Licensing and related advisory matters in India then please feel free to get in touch with SJ EXIM Services.
We offer Legal advice and litigation support in matters related to Indirect Tax-Customs, FTP, other Indirect Tax matters & Arbitration law, all sorts of Central licensing and related matters. Come and explore the new way of doing business with us!
Source: CDSCO
Handy Download:
Connect with us for more-
@ Team S J EXIM SERVICES, New Delhi, IN
CP: Ms. Shubhra Jha, Founder
Tel: +91-11-4999 2707 I +91-9999005693
Web: www.sjexim.services
EMAIL: operations@sjexim.services I shubhra@sjexim.services
Facebook: www.facebook.com/sjeximservices
LinkedIn: https://www.linkedin.com/company/90794255/admin/feed/posts/
YouTube: https://www.youtube.com/@sjeximIndia
Subscribe our WhatsApp Channel: https://whatsapp.com/channel/0029VaTxDT8JZg4CHEOSoK47
Subscribe our Telegram Channel: https://t.me/sjeximindia
Leave a ReplyCancel reply